| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus, Human | 11 | 2023 | 241 | 1.740 |
Why?
|
| Respiratory Syncytial Virus Infections | 16 | 2023 | 396 | 1.610 |
Why?
|
| Emergency Medicine | 6 | 2026 | 172 | 1.580 |
Why?
|
| Pharmacists | 4 | 2026 | 104 | 1.540 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 7 | 2021 | 82 | 1.280 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2026 | 46 | 0.940 |
Why?
|
| Viral Fusion Proteins | 6 | 2021 | 74 | 0.880 |
Why?
|
| Palivizumab | 4 | 2023 | 49 | 0.880 |
Why?
|
| Hemorrhage | 2 | 2025 | 485 | 0.880 |
Why?
|
| Anticoagulants | 3 | 2025 | 601 | 0.840 |
Why?
|
| Models, Statistical | 1 | 2025 | 483 | 0.770 |
Why?
|
| Trauma Centers | 1 | 2024 | 216 | 0.760 |
Why?
|
| Critical Care | 2 | 2026 | 686 | 0.750 |
Why?
|
| Patient Care Team | 1 | 2026 | 559 | 0.710 |
Why?
|
| Antiviral Agents | 10 | 2018 | 805 | 0.700 |
Why?
|
| Anticonvulsants | 1 | 2024 | 363 | 0.700 |
Why?
|
| Antibodies, Neutralizing | 9 | 2023 | 524 | 0.650 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2024 | 327 | 0.630 |
Why?
|
| Sigmodontinae | 12 | 2023 | 45 | 0.590 |
Why?
|
| Stroke | 2 | 2026 | 1060 | 0.560 |
Why?
|
| Aerosols | 10 | 2017 | 57 | 0.440 |
Why?
|
| Respiratory Syncytial Viruses | 6 | 2016 | 156 | 0.440 |
Why?
|
| Antibodies, Viral | 12 | 2022 | 1171 | 0.430 |
Why?
|
| Orthomyxoviridae Infections | 4 | 2014 | 56 | 0.400 |
Why?
|
| Drug Resistance, Viral | 4 | 2023 | 57 | 0.390 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2017 | 131 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 2 | 2018 | 392 | 0.370 |
Why?
|
| Drug Therapy | 3 | 2024 | 85 | 0.360 |
Why?
|
| Lung | 8 | 2023 | 1535 | 0.350 |
Why?
|
| Ribavirin | 2 | 2009 | 85 | 0.330 |
Why?
|
| Pneumonia | 2 | 2017 | 340 | 0.320 |
Why?
|
| Emergency Service, Hospital | 3 | 2026 | 1218 | 0.290 |
Why?
|
| Influenza, Human | 3 | 2014 | 707 | 0.290 |
Why?
|
| Professional Role | 2 | 2026 | 78 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 567 | 0.280 |
Why?
|
| Camptothecin | 3 | 2004 | 76 | 0.280 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 97 | 0.280 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 134 | 0.280 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 75 | 0.260 |
Why?
|
| Animals | 32 | 2023 | 33706 | 0.250 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 4646 | 0.250 |
Why?
|
| Humans | 40 | 2026 | 130444 | 0.250 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2025 | 7 | 0.220 |
Why?
|
| Hemostatics | 1 | 2025 | 58 | 0.210 |
Why?
|
| Blood Coagulation | 1 | 2025 | 134 | 0.210 |
Why?
|
| Neurology | 1 | 2026 | 116 | 0.210 |
Why?
|
| Hematoma | 1 | 2025 | 85 | 0.210 |
Why?
|
| Thrombolytic Therapy | 1 | 2025 | 191 | 0.200 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 182 | 0.200 |
Why?
|
| Cerebral Hemorrhage | 1 | 2025 | 156 | 0.200 |
Why?
|
| Time-to-Treatment | 1 | 2025 | 209 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2015 | 297 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 267 | 0.190 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 498 | 0.190 |
Why?
|
| Immunity, Innate | 2 | 2019 | 405 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2015 | 350 | 0.180 |
Why?
|
| Thrombelastography | 1 | 2023 | 69 | 0.180 |
Why?
|
| Administration, Inhalation | 6 | 2015 | 193 | 0.180 |
Why?
|
| Influenza A virus | 3 | 2013 | 145 | 0.180 |
Why?
|
| Societies, Medical | 1 | 2026 | 792 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2009 | 1813 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1484 | 0.170 |
Why?
|
| Rabies Vaccines | 1 | 2021 | 11 | 0.170 |
Why?
|
| Rabies | 1 | 2021 | 11 | 0.170 |
Why?
|
| ADP Ribose Transferases | 1 | 2020 | 20 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 352 | 0.160 |
Why?
|
| Liposomes | 7 | 2009 | 197 | 0.160 |
Why?
|
| Lung Neoplasms | 6 | 2009 | 1546 | 0.160 |
Why?
|
| Mice | 18 | 2020 | 18182 | 0.160 |
Why?
|
| Bacterial Toxins | 1 | 2020 | 170 | 0.150 |
Why?
|
| Vaccines, Attenuated | 2 | 2016 | 174 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2015 | 156 | 0.150 |
Why?
|
| United States | 2 | 2026 | 11991 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 176 | 0.150 |
Why?
|
| Seizures | 1 | 2024 | 886 | 0.150 |
Why?
|
| Aluminum Compounds | 1 | 2018 | 16 | 0.140 |
Why?
|
| Antibody Affinity | 1 | 2018 | 37 | 0.140 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2019 | 60 | 0.140 |
Why?
|
| Cell Line | 7 | 2018 | 2553 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 1 | 2018 | 34 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 702 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 786 | 0.140 |
Why?
|
| Virus Internalization | 2 | 2015 | 57 | 0.140 |
Why?
|
| Phosphates | 1 | 2018 | 112 | 0.140 |
Why?
|
| Oseltamivir | 1 | 2017 | 19 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 93 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2017 | 37 | 0.130 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2017 | 121 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 83 | 0.130 |
Why?
|
| Rats | 3 | 2018 | 3374 | 0.130 |
Why?
|
| Vitamin E | 2 | 2009 | 62 | 0.130 |
Why?
|
| Epitopes | 1 | 2018 | 323 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 130 | 0.130 |
Why?
|
| Female | 17 | 2025 | 70504 | 0.120 |
Why?
|
| Toll-Like Receptor 6 | 2 | 2017 | 5 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2017 | 22 | 0.120 |
Why?
|
| Vaccination | 2 | 2021 | 1057 | 0.120 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 48 | 0.120 |
Why?
|
| Paclitaxel | 3 | 2009 | 129 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 382 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 56 | 0.120 |
Why?
|
| Single-Domain Antibodies | 1 | 2015 | 8 | 0.120 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 679 | 0.110 |
Why?
|
| Autophagy | 2 | 2020 | 419 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 383 | 0.110 |
Why?
|
| Virus Attachment | 1 | 2015 | 32 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2018 | 301 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2009 | 235 | 0.110 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2008 | 61 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2025 | 708 | 0.110 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 10 | 0.110 |
Why?
|
| Adult | 8 | 2024 | 31098 | 0.110 |
Why?
|
| Drug Carriers | 2 | 2014 | 119 | 0.110 |
Why?
|
| Viral Envelope Proteins | 1 | 2015 | 155 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2016 | 499 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4057 | 0.100 |
Why?
|
| Male | 12 | 2025 | 64570 | 0.100 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2013 | 8 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2013 | 4 | 0.100 |
Why?
|
| alpha-Tocopherol | 2 | 2004 | 36 | 0.100 |
Why?
|
| Germinal Center | 1 | 2013 | 36 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2015 | 177 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 5 | 2016 | 977 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2014 | 143 | 0.100 |
Why?
|
| Adenoviridae | 2 | 2014 | 581 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2014 | 194 | 0.090 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2013 | 59 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2014 | 892 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 236 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 508 | 0.080 |
Why?
|
| Wound Healing | 1 | 2014 | 486 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2009 | 101 | 0.080 |
Why?
|
| Macrophages | 1 | 2014 | 661 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2023 | 1319 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2013 | 436 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 1097 | 0.080 |
Why?
|
| Asthma | 1 | 2018 | 920 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 148 | 0.070 |
Why?
|
| Rotenone | 1 | 2009 | 12 | 0.070 |
Why?
|
| Gene Expression | 2 | 2015 | 1482 | 0.070 |
Why?
|
| Proteins | 1 | 2014 | 1006 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12838 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 711 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 78 | 0.070 |
Why?
|
| Interferons | 1 | 2009 | 138 | 0.070 |
Why?
|
| Dogs | 2 | 2015 | 615 | 0.070 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 185 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2013 | 759 | 0.070 |
Why?
|
| Periodicals as Topic | 2 | 2021 | 182 | 0.070 |
Why?
|
| Mutation | 2 | 2018 | 6062 | 0.070 |
Why?
|
| Macrophages, Alveolar | 2 | 2019 | 52 | 0.060 |
Why?
|
| Genes, ras | 2 | 2009 | 95 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 2012 | 349 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 1480 | 0.060 |
Why?
|
| Fullerenes | 1 | 2005 | 4 | 0.060 |
Why?
|
| Indazoles | 2 | 2015 | 35 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 3711 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 553 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2005 | 70 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1284 | 0.060 |
Why?
|
| Phenols | 1 | 2005 | 73 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 79 | 0.050 |
Why?
|
| Neutralization Tests | 2 | 2015 | 226 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 1324 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1605 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1714 | 0.050 |
Why?
|
| Viral Load | 2 | 2016 | 412 | 0.050 |
Why?
|
| Propensity Score | 1 | 2025 | 271 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 135 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2009 | 4662 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2004 | 132 | 0.050 |
Why?
|
| Hirudins | 1 | 2023 | 39 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2023 | 55 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 152 | 0.050 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2002 | 33 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2023 | 355 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 786 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2002 | 34 | 0.040 |
Why?
|
| Pyridines | 1 | 2003 | 256 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 849 | 0.040 |
Why?
|
| Piperidines | 1 | 2003 | 221 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2004 | 223 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2002 | 80 | 0.040 |
Why?
|
| Administration, Intranasal | 2 | 2014 | 130 | 0.040 |
Why?
|
| Heparin | 1 | 2023 | 206 | 0.040 |
Why?
|
| Urinalysis | 1 | 2002 | 72 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2014 | 195 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 313 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 227 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 11 | 0.040 |
Why?
|
| Bibliometrics | 1 | 2021 | 37 | 0.040 |
Why?
|
| Injections, Intradermal | 1 | 2021 | 29 | 0.040 |
Why?
|
| Organ Size | 1 | 2002 | 408 | 0.040 |
Why?
|
| Seasons | 1 | 2022 | 335 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1479 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2015 | 311 | 0.040 |
Why?
|
| Solvents | 1 | 2019 | 39 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 20875 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1413 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 130 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2023 | 686 | 0.040 |
Why?
|
| Phospholipids | 1 | 2019 | 100 | 0.040 |
Why?
|
| Smoke | 1 | 2019 | 79 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 93 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 1087 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 812 | 0.040 |
Why?
|
| Nicotine | 1 | 2019 | 115 | 0.040 |
Why?
|
| Time Factors | 2 | 2025 | 6175 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 169 | 0.030 |
Why?
|
| Critical Illness | 1 | 2023 | 624 | 0.030 |
Why?
|
| src Homology Domains | 1 | 2018 | 34 | 0.030 |
Why?
|
| Peptides | 1 | 2021 | 707 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 428 | 0.030 |
Why?
|
| Delirium | 1 | 2019 | 66 | 0.030 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 96 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2019 | 141 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2012 | 236 | 0.030 |
Why?
|
| Body Weight | 1 | 2002 | 985 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2002 | 711 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 56 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2023 | 5048 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 236 | 0.030 |
Why?
|
| Vero Cells | 1 | 2016 | 115 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2016 | 61 | 0.030 |
Why?
|
| Reverse Genetics | 1 | 2016 | 15 | 0.030 |
Why?
|
| Apoptosis | 3 | 2009 | 1825 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2019 | 267 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 287 | 0.030 |
Why?
|
| Pain | 1 | 2019 | 437 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 480 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1263 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 290 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 425 | 0.030 |
Why?
|
| Respiratory System | 1 | 2016 | 95 | 0.030 |
Why?
|
| Cell Fusion | 1 | 2015 | 32 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 881 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1592 | 0.030 |
Why?
|
| Pichia | 1 | 2015 | 56 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17619 | 0.030 |
Why?
|
| Bronchi | 1 | 2015 | 98 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2019 | 525 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 713 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 970 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2015 | 56 | 0.030 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2014 | 3 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2015 | 112 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2015 | 83 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2016 | 336 | 0.030 |
Why?
|
| Sepsis | 1 | 2019 | 494 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 117 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 99 | 0.030 |
Why?
|
| Osteopontin | 1 | 2014 | 54 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 688 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2014 | 29 | 0.030 |
Why?
|
| Complement C1q | 1 | 2014 | 18 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 20 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 4696 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2004 | 95 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2013 | 52 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 134 | 0.030 |
Why?
|
| Infant | 2 | 2023 | 13308 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 2013 | 84 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 308 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 235 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 291 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 9 | 0.020 |
Why?
|
| Immunization | 1 | 2014 | 269 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2014 | 324 | 0.020 |
Why?
|
| Virus Replication | 1 | 2015 | 609 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1061 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3662 | 0.020 |
Why?
|
| Prostate | 1 | 2014 | 402 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 905 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 525 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 765 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 130 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 267 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 873 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 782 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2009 | 2460 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1651 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6421 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 506 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 226 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 237 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2009 | 362 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 355 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 2330 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 317 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 226 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 978 | 0.020 |
Why?
|
| Middle Aged | 2 | 2025 | 28392 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2009 | 356 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1014 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 3812 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 280 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 27 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 15036 | 0.010 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 63 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 112 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 356 | 0.010 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2004 | 1 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 219 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 120 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 62 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 88 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 88 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 242 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 340 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 974 | 0.010 |
Why?
|
| Point Mutation | 1 | 2002 | 332 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 404 | 0.010 |
Why?
|
| Child | 1 | 2021 | 26243 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 20873 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 759 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2004 | 420 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2002 | 1004 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1673 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5185 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 1366 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 6768 | 0.010 |
Why?
|